Represents the number of licenses terminated.

No definition available.

Name:	imgn_NumberOfLicensesTerminated
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=imgn_AmgenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_PhaseIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=imgn_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=imgn_LicenseAndMilestoneFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements - Amgen/Oxford BioTherapeutics (Details) $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2000 USD ($) item	Oct. 31, 2013 USD ($)
Collaborative Agreements disclosures
Revenue from contract with customer	$ 44,864	$ 13,281	$ 15,542	$ 8,584	$ 13,416	$ 10,928	$ 9,287	$ 19,815	$ 39,448	$ 8,480	$ 39,020	$ 28,499	$ 82,271	$ 53,446	$ 115,447
Amgen/Oxford BioTherapeutics
Collaborative Agreements disclosures
Revenue from contract with customer													4,000
Number of single-target licenses \| item																4
Number of licenses terminated \| item																4
Amgen/Oxford BioTherapeutics \| Development milestones
Collaborative Agreements disclosures
Potential milestone payment																	$ 9,000
Amgen/Oxford BioTherapeutics \| Phase 2 clinical trial
Collaborative Agreements disclosures
Potential milestone payment	3,000												3,000
Amgen/Oxford BioTherapeutics \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payment																	20,000
Amgen/Oxford BioTherapeutics \| Milestone payments
Collaborative Agreements disclosures
Potential milestone payment																	5,000
Upfront payment \| Amgen/Oxford BioTherapeutics
Collaborative Agreements disclosures
Revenue from contract with customer																$ 1,000
License and milestone fees
Collaborative Agreements disclosures
Revenue from contract with customer	$ 29,551	$ 79	$ 5,079	$ 79	$ 1,747	$ 672	$ 1,321	$ 11,540	$ 29,580	$ 79	$ 31,080	$ 18,730	$ 34,788	$ 15,280	$ 79,469
License and milestone fees \| Amgen/Oxford BioTherapeutics
Collaborative Agreements disclosures
Potential milestone payment																	$ 34,000